Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.06 (150.00%)

    Silver Spruce Resources

    MCap

    CAD3m

    Last close

    CAD0.02

    ▲ 0.01 (100.00%)

    Actinogen Medical

    MCap

    AUD48m

    Last close

    AUD0.03

    ▲ 0.01 (50.00%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

Associated equity: OpGen

OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. It has the technology to detect pathogens and predict resistance. Through the dual platform offering of the AMR Gene Panel and Unyvero, it can provide diagnostic results in hours instead of days.

View this company

OpGen — 5 videos in collection

This interactive webinar with OpGen’s CEO Oliver Schacht, CFO Tim Dec and COO Johannes Bacher highlights recent progress in the fight against Antimicrobial Resistance. The presentation includes updates on R&D progress, FDA and NMPA regulatory reviews and pending approvals, upcoming clinical trials, and business development and partnering opportunities. The speakers also comment on key corporate development topics around the shareholder support required to authorise new shares for future strategic development and financing.

< Previous
Next >

You may also be interested in these:

Healthcare

OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Healthcare

OpGen: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free